# A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

> **NCT04084678** · PHASE3 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- PAH
- Pulmonary Hypertension
- Hypertension
- Connective Tissue Disease
- Familial Primary Pulmonary Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension, Pulmonary
- Lung Diseases
- Respiratory Tract Disease
- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Ralinepag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04084678
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-20
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-04-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084678, "A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04084678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*